Company news
Inoviq Ltd (ASX:IIQ) news
Inoviq Ltd news releases on 6ix. Latest, Nov 16, 2023: Bell Potter Healthcare Conference Investor Presentation
Press releases — page 2
Bell Potter Healthcare Conference Investor Presentation
November 15, 2023
ANSEV Meeting Presentations
November 7, 2023
Appendix 4C and Quarterly Activities Report - September 2023
October 29, 2023
ASX Small and Mid-Cap Conference Investor Presentation
September 19, 2023
IIQ and ResearchDx sign USA EXO-NET Services Agreement
September 4, 2023
EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY
August 8, 2023
INOVIQ Investor Briefing
July 31, 2023
Appendix 4C and Quarterly Activities Report - June 2023
July 27, 2023
INOVIQ and Promega announce Global Joint Marketing Agreement
July 5, 2023
SubB2M/CA15.3 Clinical Validation Data Investor Presentation
June 29, 2023
Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test
June 26, 2023
ISEV Meeting Presentations
May 18, 2023
Appendix 4C and Quarterly Activities Report - March 2023
April 27, 2023
Appendix 4D and Half Year Financial Report
February 23, 2023
Positive results for SubB2M Breast Cancer Test
February 7, 2023
Appendix 4C & Quarterly Activities Report - December 2022
January 30, 2023
Positive EXO-NET Results in Ovarian Cancer
December 12, 2022
MST Access Diagnostics Forum Presentation
December 4, 2022
CEO AGM Presentation
November 27, 2022
INOVIQ Settles Legal Proceedings
November 27, 2022
Commercial and R&D Update
November 24, 2022
Healthcare Conference Investor Presentation
November 10, 2022
IIQ Appendix 4C & Quarterly Activities Report-September 2022
October 27, 2022
Canadian Patent Granted for BARD1 Technology
October 27, 2022
Receipt of R&D Tax Incentive Refund
October 13, 2022
INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform
October 12, 2022
2022 Annual Report and update on results
September 27, 2022
IIQ Investor Presentation
August 9, 2022
IIQ Appendix 4C & Quarterly Activities Report - June 2022
July 26, 2022
Positive SubB2M IHC Results for Melanoma
July 26, 2022
hTERT US Patent Granted
July 21, 2022
INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out
July 20, 2022
SubB2M US Patent Grant and Program Update
July 1, 2022
Australian Patent Granted for SubB2M Technology
May 2, 2022
INOVIQ Key Manufacturing Agreement to Advance SubB2M tests
May 1, 2022
IIQ Appendix 4C & Quarterly Activities Report - March 2022
April 29, 2022
INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests
April 4, 2022
INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test
March 31, 2022
Update on Legal Proceedings and BARD1 Autoantibody Program
March 27, 2022
Brazilian Patent Issued for Lung & Colorectal Cancer
February 22, 2022
Appendix 4C & Quarterly Activities Report
January 30, 2022
AGM Presentation
November 29, 2021
BARD1 Appoints New CSO
September 16, 2021
BARD1 Share Purchase Plan Completed Oversubscribed
August 22, 2021
Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test
August 16, 2021
BARD1 LODGES SPP AND OPTIONS PROSPECTUS
July 30, 2021
BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data
July 28, 2021
Updated Investor Presentation
July 23, 2021
BARD1 $15m Placement to Accelerate Cancer Diagnostic Program
July 22, 2021
BARD1 Investor Presentation
July 7, 2021